$THC

Romo Tammy sold $2.0M of THC

Romo Tammy sold 7,422 shares of TENET HEALTHCARE CORP (THC) at an average of $263.03 ($260.83–$264.15, $1.95M total) across 2 trades over 2026-08-06 to 2026-08-07.

Original reporting
SEC EDGAR · Romo Tammy
Published Aug 11, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and can influence short-term sentiment, but it does not provide new information about Tenet’s operations, financial results, or guidance.

02

Market read

Traders may monitor insider selling as a sentiment input, but the filing alone is not a fundamental catalyst.

03

What to watch

Insider sales often reflect diversification, taxes, or pre-scheduled liquidity needs; the article provides no reason for the sale or any link to company performance.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-10 for trades dated 2026-08-06 to 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare Corp, reported by director Romo Tammy.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Romo Tammy filed Form 4 showing an open-market sale of 7,422 shares at about $260.83 to $264.15.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan and no accompanying operational or guidance change disclosed in the text.

Market effects

No sector-level implications are provided; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is not tied to a stated 10b5-1 plan in the text, some traders may overinterpret it as bearish despite being a small, routine insider transaction.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider transaction disclosure.

  • Romo Tammy

    Director who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

$THCMedAI 8/10

Tenet Healthcare stock hits all-time high at 270.79 USD

Tenet Healthcare (THC) stock hit an all-time high of $270.79, up 54.4% over the past year. The company reported strong Q2 2026 earnings, exceeding expectations with $6.12 EPS on $5.63B revenue. Analysts raised price targets, with UBS setting the highest at $308. THC's P/E ratio is 10.46, and PEG ratio is 0.15, suggesting attractive valuation.

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.